Advancing in vitro assessment of iodide uptake inhibition: integrating a novel biotransformation pretreatment step
Archives of Toxicology · 2025
DOI: 10.1007/s00204-025-04034-y ↗Kurz gefasst
Fachartikel in der Zeitschrift Archives of Toxicology, 2025. Verfasst von Puja Kumari und 3 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Science, RECETOX, Masaryk University, Kamenice 753/5, Pavilion A29, Kotlarska 2, 625 00, Brno, Czech Republic. Hauptthemen laut MEDLINE: Symporters, Iodides, Endocrine Disruptors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministerstvo Školství, Mládeže a Tělovýchovy, Horizon 2020 Framework Programme, Masaryk University.
Abstract (Originalsprache)
Thyroid hormones (TH) are essential for vertebrate development, growth, and metabolism. The increasing prevalence of anthropogenic chemicals with TH-disrupting potential highlights the urgent need for advanced methods to assess their impact on TH homeostasis. Inhibition of the sodium–iodide symporter (NIS) has been identified as a key molecular initiating event disrupting the TH system across species, with significant relevance for diagnostic and therapeutic applications in various carcinomas. This study presents in vitro bioassays for evaluating the effects of compounds on iodide uptake into cells, a critical step in TH production mediated by NIS. Two novel stably transfected human cell lines overexpressing human NIS were employed along with a rat thyroid cell model FRTL-5, using colorimetric Sandell–Kolthoff (SK) reaction for iodide detection. The results from 23 model compounds demonstrate comparability across various in vitro models and radioactivity-based assays. To enhance physiological relevance, an external biotransformation system (BTS) was integrated and optimized for live-cell compatibility without inducing cytotoxicity or interfering with the assay. Compounds identified as NIS inhibitors were evaluated using the BTS-augmented assay, which revealed that metabolic activity mitigated the inhibitory effects of some chemicals. The augmented assay exhibited strong concordance with in vivo and in silico biotransformation data. Protein sequence alignment confirmed high conservation of NIS functional domains across vertebrates, reinforcing the cross-species applicability of the findings. The SK-based NIS assay, with optional BTS integration, represents a sensitive, robust, and high-throughput amendable alternative to radioactivity-based methods, for characterizing the impacts of individual compounds and complex environmental mixtures on TH homeostasis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Science, RECETOX, Masaryk University, Kamenice 753/5, Pavilion A29, Kotlarska 2, 625 00, Brno, Czech Republic.
- Department of Biology and Environmental Science, Linnaeus University, SE-39182 Kalmar, Sweden.
- Faculty of Science, RECETOX, Masaryk University, Kamenice 753/5, Pavilion A29, Kotlarska 2, 625 00, Brno, Czech Republic. klara.hilscherova@recetox.muni.cz.
ORCID-Profile: Klára Hilscherová
Förderung
- Ministerstvo Školství, Mládeže a Tělovýchovy
- Horizon 2020 Framework Programme
- Masaryk University
Zitieren
APA
Kumari, P., Lungu-Mitea, S., Novák, J., & Hilscherová, K. (2025). Advancing in vitro assessment of iodide uptake inhibition: integrating a novel biotransformation pretreatment step. Archives of Toxicology. https://doi.org/10.1007/s00204-025-04034-y
Vancouver
Kumari P, Lungu-Mitea S, Novák J, Hilscherová K. Advancing in vitro assessment of iodide uptake inhibition: integrating a novel biotransformation pretreatment step. Archives of Toxicology. 2025. doi:10.1007/s00204-025-04034-y
BibTeX
@article{Kumari2025,
author = {Kumari, Puja and Lungu-Mitea, Sebastian and Novák, Jiří and Hilscherová, Klára},
title = {Advancing in vitro assessment of iodide uptake inhibition: integrating a novel biotransformation pretreatment step},
journal = {Archives of Toxicology},
year = {2025},
doi = {10.1007/s00204-025-04034-y}
}
EUVIMED